Cell death pathways – potential therapeutic targets

References

• Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. (2000). An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60(21):6101–10.
   PubMedGoogle Scholar
• Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. (2002). Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277(46):44236–43.
   PubMedGoogle Scholar
• Ashkenazi A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2(6):420–30.
   PubMedGoogle Scholar
• Ashkenazi A, Dixit VM. (1998). Death receptors: signaling and modulation. Science 281:1305–8.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Herbst RS. (2008). To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118(6):1979–90.
   PubMedGoogle Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104(2):155–62.
   PubMedGoogle Scholar
• Baehrecke EH. (2002). How death shapes life during development. Nat Rev Mol Cell Biol 3(10):779–87.
   PubMedGoogle Scholar
• Bratton SB, MacFarlane M, Cain K, Cohen GM. (2000). Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res 256(1):27–33.
   PubMedGoogle Scholar
• Cain K, Bratton SB, Cohen GM. (2002). The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie 84(2–3):203–14.
   PubMedGoogle Scholar
• Cain K, Brown DG, Langlais C, Cohen GM. (1999). Caspase activation involves the formation of the aposome, a large (approximately 700 kDa) caspase-activating complex. J Biol Chem 274(32):22686–92.
   PubMedGoogle Scholar
• Cohen GM. (1997). Caspases: the executioners of apoptosis. Biochem J 326(Pt 1):1–16.
   PubMedGoogle Scholar
• Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. (2004). X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 64(9):3006–8.
   PubMedGoogle Scholar
• Danial NN, Korsmeyer SJ. (2004). Cell death: critical control points. Cell 116(2):205–19.
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. (2007). Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117(1):112–21.
   PubMedGoogle Scholar
• Deveraux QL, Takahashi R, Salvesen GS, Reed JC. (1997). X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388(6639):300–4.
   PubMedGoogle Scholar
• Dyer MJ, MacFarlane M, Cohen GM. (2007). Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 25(28):4505–6.
   PubMedGoogle Scholar
• Fesik SW. (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5(11):876–85.
   PubMedGoogle Scholar
• Frantz S. (2004). Lessons learnt from Genasense’s failure. Nat Rev Drug Discov 3(7):542–3.
   PubMedGoogle Scholar
• Fulda S, Wick W, Weller M, Debatin KM. (2002). Smac agonists sensitize for Apo2L/TRAIL – or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8(8):808–15.
   PubMedGoogle Scholar
• Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, et al. (2009). Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (Epub ahead of print: 17 April 2009; doi:10.1038/cdd.2009.44).
   Google Scholar
• Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC, Kroemer G. (2008). To die or not to die: that is the autophagic question. Curr Mol Med 8(2):78–91.
   PubMedGoogle Scholar
• Gaulard P, d’Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J, Mason DY. (1992). Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140(5):1089–95.
   PubMedGoogle Scholar
• Golstein P, Kroemer G. (2007). Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 32(1):37–43.
   PubMedGoogle Scholar
• Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M. (2005). Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 92(4):736–42.
   PubMedGoogle Scholar
• Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC. (2003). Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9(7):2826–36.
   PubMedGoogle Scholar
• Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. (2004). Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl. 2):S193–206.
   Google Scholar
• Johnstone RW, Frew AJ, Smyth MJ. (2008). The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8(10):782–98.
   PubMedGoogle Scholar
• Kerr JF, Wyllie AH, Currie AR. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26(4):239–57.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. (2008). Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151–75.
   PubMedGoogle Scholar
• Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G; Nomenclature Committee on Cell Death. (2005). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 12(Suppl. 2):1463–7.
   PubMedGoogle Scholar
• Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G; Nomenclature Committee on Cell Death 2009. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16(1):3–11.
   PubMed Web of Science ®Google Scholar
• Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. (2002). Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc 124(40):11838–9.
   PubMedGoogle Scholar
• Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7(4):383–5.
   PubMedGoogle Scholar
• MacFarlane M. (2003). TRAIL-induced signalling and apoptosis. Toxicol Lett 139(2–3):89–97.
   PubMedGoogle Scholar
• MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. (1997a). Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272(41):25417–20.
   PubMedGoogle Scholar
• MacFarlane M, Cain K, Sun XM, Alnemri ES, Cohen GM. (1997b). Processing/activation of at least four interleukin-1beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells. J Cell Biol 137(2):469–79.
   PubMedGoogle Scholar
• MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM. (2002). Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21(44):6809–18.
   PubMedGoogle Scholar
• MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM. (2005a). Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12(7):773–82.
   PubMedGoogle Scholar
• MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. (2005b). TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65(24):11265–70.
   PubMedGoogle Scholar
• MacFarlane M, Williams AC. (2004). Apoptosis and disease: a life or death decision. EMBO Rep 5(7):674–8.
   PubMedGoogle Scholar
• Nagata S. (1997). Apoptosis by death factor. Cell 88(3):355–65.
   PubMedGoogle Scholar
• Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM. (2007). TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 139(4):568–77.
   PubMedGoogle Scholar
• O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR. (2007). Randomized Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25(9): 1114–20.
   PubMedGoogle Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677–81.
   PubMedGoogle Scholar
• Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H, Fesik SW. (2004). Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47(18):4417–26.
   PubMedGoogle Scholar
• Peter ME, Krammer PH. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10(1):26–35.
   PubMedGoogle Scholar
• Petros AM, Olejniczak ET, Fesik SW. (2004). Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644(2–3):83–94.
   PubMedGoogle Scholar
• Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Tomita Y, Krajewski K, Roller PP, Wang S. (2004). Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem 47(17):4147–50.
   PubMedGoogle Scholar
• Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. (1999). Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274(8):5053–60.
   PubMedGoogle Scholar
• Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421–8.
   PubMedGoogle Scholar
• Twiddy D, Brown DG, Adrain C, Jukes R, Martin SJ, Cohen GM, MacFarlane M, Cain K. (2004). Pro-apoptotic proteins released from the mitochondria regulate the protein composition and caspase-processing activity of the native Apaf-1/caspase-9 apoptosome complex. J Biol Chem 279(19):19665–82.
   Google Scholar
• Van Loo G, Saelens X, Van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. (2002). The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 9(10):1031–42.
   PubMedGoogle Scholar
• Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, Cohen GM. (2008). A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15(5):820–30.
   PubMed Web of Science ®Google Scholar
• Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, MacFarlane M, Cohen GM, Manns MP, Schulze-Osthoff K, Bantel H. (2007). Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46(5):1498–508.
   PubMedGoogle Scholar
• Vucic D, Fairbrother WJ. (2007). The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13(20):5995–6000.
   PubMed Web of Science ®Google Scholar
• Wu H, Tschopp J, Lin SC. (2007). Smac mimetics and TNFalpha: a dangerous liaison? Cell 131(4):655–8.
   PubMedGoogle Scholar
• Youle RJ, Strasser A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47–59.
   PubMed Web of Science ®Google Scholar